- Home
- PLX vs HLVX Comparison
PLX vs HLVX Comparison
Compare PLX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- HLVX
- Stock Information
- Founded
- PLX 1993
- HLVX 2020
- Country
- PLX Israel
- HLVX United States
- Employees
- PLX N/A
- HLVX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- HLVX Health Care
- Exchange
- PLX Nasdaq
- HLVX Nasdaq
- Market Cap
- PLX 79.4M
- HLVX 87.6M
- IPO Year
- PLX 1998
- HLVX 2022
- Fundamental
- Price
- PLX $1.68
- HLVX $1.82
- Analyst Decision
- PLX
- HLVX Hold
- Analyst Count
- PLX 0
- HLVX 5
- Target Price
- PLX N/A
- HLVX $2.33
- AVG Volume (30 Days)
- PLX 439.0K
- HLVX 133.3K
- Earning Date
- PLX 11-14-2024
- HLVX 11-07-2024
- Dividend Yield
- PLX N/A
- HLVX N/A
- EPS Growth
- PLX N/A
- HLVX N/A
- EPS
- PLX N/A
- HLVX N/A
- Revenue
- PLX $45,667,000.00
- HLVX N/A
- Revenue This Year
- PLX N/A
- HLVX N/A
- Revenue Next Year
- PLX $88.94
- HLVX N/A
- P/E Ratio
- PLX N/A
- HLVX N/A
- Revenue Growth
- PLX N/A
- HLVX N/A
- 52 Week Low
- PLX $0.82
- HLVX $1.55
- 52 Week High
- PLX $1.90
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- PLX 74.56
- HLVX 44.86
- Support Level
- PLX $1.14
- HLVX $1.80
- Resistance Level
- PLX $1.75
- HLVX $2.02
- Average True Range (ATR)
- PLX 0.12
- HLVX 0.07
- MACD
- PLX 0.05
- HLVX -0.01
- Stochastic Oscillator
- PLX 87.29
- HLVX 17.02
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.